+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cystic Fibrosis - Pipeline Review, H2 2018

  • ID: 4620361
  • Drug Pipelines
  • 435 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AGILeBiotics BV
  • Calithera Biosciences Inc
  • ethris GmbH
  • Insmed Inc
  • Novartis AG
  • ReveraGen BioPharma Inc
  • MORE
Cystic Fibrosis - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

Report Highlights:

This latest pipeline guide Cystic Fibrosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 29, 27, 60 and 30 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AGILeBiotics BV
  • Calithera Biosciences Inc
  • ethris GmbH
  • Insmed Inc
  • Novartis AG
  • ReveraGen BioPharma Inc
  • MORE
Introduction

Cystic Fibrosis - Overview

Cystic Fibrosis - Therapeutics Development

Cystic Fibrosis - Therapeutics Assessment

Cystic Fibrosis - Companies Involved in Therapeutics Development

Cystic Fibrosis - Drug Profiles

Cystic Fibrosis - Dormant Projects

Cystic Fibrosis - Discontinued Products

Cystic Fibrosis - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H2 2018

Cystic Fibrosis - Pipeline by Advanced Inhalation Therapies (AIT) Ltd, H2 2018

Cystic Fibrosis - Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by AGILeBiotics BV, H2 2018

Cystic Fibrosis - Pipeline by Alaxia SAS, H2 2018

Cystic Fibrosis - Pipeline by AlgiPharma AS, H2 2018

Cystic Fibrosis - Pipeline by AmpliPhi Biosciences Corp, H2 2018

Cystic Fibrosis - Pipeline by Antabio SAS, H2 2018

Cystic Fibrosis - Pipeline by Arch Biopartners Inc, H2 2018

Cystic Fibrosis - Pipeline by Arcturus Therapeutics Ltd, H2 2018

Cystic Fibrosis - Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by AstraZeneca Plc, H2 2018

Cystic Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Cystic Fibrosis - Pipeline by Calithera Biosciences Inc, H2 2018

Cystic Fibrosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Celtaxsys Inc, H2 2018

Cystic Fibrosis - Pipeline by Chiesi Farmaceutici SpA, H2 2018

Cystic Fibrosis - Pipeline by Cilian AG, H2 2018

Cystic Fibrosis - Pipeline by CRISPR Therapeutics, H2 2018

Cystic Fibrosis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Cyclenium Pharma Inc, H2 2018

Cystic Fibrosis - Pipeline by DiscoveryBiomed Inc, H2 2018

Cystic Fibrosis - Pipeline by Editas Medicine Inc, H2 2018

Cystic Fibrosis - Pipeline by Eloxx Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Enterprise Therapeutics Ltd, H2 2018

Cystic Fibrosis - Pipeline by Errant Gene Therapeutics LLC, H2 2018

Cystic Fibrosis - Pipeline by ethris GmbH, H2 2018

Cystic Fibrosis - Pipeline by Evaxion Biotech ApS, H2 2018

Cystic Fibrosis - Pipeline by Galapagos NV, H2 2018

Cystic Fibrosis - Pipeline by Generation Bio Corp, H2 2018

Cystic Fibrosis - Pipeline by Grifols SA, H2 2018

Cystic Fibrosis - Pipeline by Grupo Praxis Pharmaceutical SA, H2 2018

Cystic Fibrosis - Pipeline by Helperby Therapeutics Group Ltd, H2 2018

Cystic Fibrosis - Pipeline by Homology Medicines, Inc., H2 2018

Cystic Fibrosis - Pipeline by Horizon Pharma Plc, H2 2018

Cystic Fibrosis - Pipeline by ID Pharma Co Ltd, H2 2018

Cystic Fibrosis - Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Cystic Fibrosis - Pipeline by Immun System IMS AB, H2 2018

Cystic Fibrosis - Pipeline by Insmed Inc, H2 2018

Cystic Fibrosis - Pipeline by Invion Ltd, H2 2018

Cystic Fibrosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by JHL Biotech Inc, H2 2018

Cystic Fibrosis - Pipeline by Johnson & Johnson, H2 2018

Cystic Fibrosis - Pipeline by Kamada Ltd, H2 2018

Cystic Fibrosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2018

Cystic Fibrosis - Pipeline by Lamellar Biomedical Ltd, H2 2018

Cystic Fibrosis - Pipeline by Laurent Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Lexicon Pharmaceuticals Inc, H2 2018

Cystic Fibrosis - Pipeline by Microbion Corp, H2 2018

Cystic Fibrosis - Pipeline by Novabiotics Ltd, H2 2018

List of Figures

Number of Products under Development for Cystic Fibrosis, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4D Molecular Therapeutics Inc
  • Advanced Inhalation Therapies (AIT) Ltd
  • Aeolus Pharmaceuticals Inc
  • AGILeBiotics BV
  • Alaxia SAS
  • AlgiPharma AS
  • AmpliPhi Biosciences Corp
  • Antabio SAS
  • Arch Biopartners Inc
  • Arcturus Therapeutics Ltd
  • Aridis Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Calithera Biosciences Inc
  • Catabasis Pharmaceuticals Inc
  • Celtaxsys Inc
  • Chiesi Farmaceutici SpA
  • Cilian AG
  • CRISPR Therapeutics
  • Cyclacel Pharmaceuticals Inc
  • Cyclenium Pharma Inc
  • DiscoveryBiomed Inc
  • Editas Medicine Inc
  • Eloxx Pharmaceuticals Inc
  • Enterprise Therapeutics Ltd
  • Errant Gene Therapeutics LLC
  • ethris GmbH
  • Evaxion Biotech ApS
  • Galapagos NV
  • Generation Bio Corp
  • Grifols SA
  • Grupo Praxis Pharmaceutical SA
  • Helperby Therapeutics Group Ltd
  • Homology Medicines, Inc.
  • Horizon Pharma Plc
  • ID Pharma Co Ltd
  • Idorsia Pharmaceutical Ltd
  • Immun System IMS AB
  • Insmed Inc
  • Invion Ltd
  • Ionis Pharmaceuticals Inc
  • JHL Biotech Inc
  • Johnson & Johnson
  • Kamada Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lamellar Biomedical Ltd
  • Laurent Pharmaceuticals Inc
  • Lexicon Pharmaceuticals Inc
  • Microbion Corp
  • Novabiotics Ltd
  • Novartis AG
  • Onspira Therapeutics Inc
  • Paranta Biosciences Ltd
  • Parion Sciences Inc
  • Pharmaxis Ltd
  • PhaseBio Pharmaceuticals Inc
  • Polyphor AG
  • Progenra Inc
  • ProQR Therapeutics NV
  • Protalix BioTherapeutics Inc
  • Proteostasis Therapeutics Inc
  • Pulmatrix Inc
  • ReveraGen BioPharma Inc
  • Santhera Pharmaceuticals Holding AG
  • Sequoia Sciences Inc
  • Shire Plc
  • SolAeroMed Inc
  • Synedgen Inc
  • Synovo GmbH
  • Translate Bio Inc
  • Vanda Pharmaceuticals Inc
  • Verona Pharma Plc
  • Vertex Pharmaceuticals Inc
  • Vironika LLC
Note: Product cover images may vary from those shown
Adroll
adroll